Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, August 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 review on a research highlight platform.

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.